Observational studyPloS one2019
Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes.
Observational study in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Circulating levels of asprosin in children with obesity: a systematic review and meta-analysis.BMC endocrine disorders · 2024Pooled it
- Pooled it
- Cohort profile of the Heidelberg study on diabetes and complications HEIST-DiC.Scientific reports · 2025Article
- Low Serum Asprosin Levels in Fibromyalgia Syndrome: Insights from a Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2025Article
- Predictive roles of Asprosin and Gremlin-1 expression in Egyptian pediatric patients with type 1 diabetes.Scientific reports · 2025Article
- Asprosin is a Reliable Predictor of Osteoporosis in Type 2 Diabetic Postmenopausal Women: A Case-Control Study.Indian journal of clinical biochemistry : IJCB · 2025Article
- Asprosin: the potential player in combined double diabetes and hypothyroidism.Irish journal of medical science · 2024Article
- TRPC5 controls the adrenaline-mediated counter regulation of hypoglycemia.The EMBO journal · 2024Article
- Increased RBP4 and Asprosin Are Novel Contributors in Inflammation Process of Periodontitis in Obese Rats.International journal of molecular sciences · 2023Article
- Asprosin Enhances Cytokine Production by a Co-Culture of Fully Differentiated Mature Adipocytes and Macrophages Leading to the Exacerbation of the Condition Typical of Obesity-Related Inflammation.International journal of molecular sciences · 2023Article
- Asprosin promotes feeding through SK channel-dependent activation of AgRP neurons.Science advances · 2023Article
- Association of cord blood asprosin concentration with atherogenic lipid profile and anthropometric indices.Diabetology & metabolic syndrome · 2022Article
- Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by theMolecular syndromology · 2022Review
- Asprosin, a novel therapeutic candidate for painful neuropathy: an experimental study in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Sensitive asprosin detection in clinical samples reveals serum/saliva correlation and indicates cartilage as source for serum asprosin.Scientific reports · 2022Article
- Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study.Lipids in health and disease · 2021Article
- Novel Targets in Glucose Homeostasis and Obesity-Lesson from Rare Mutations.Current diabetes reports · 2020Review
- [Effect of high-fat diet and exercise on asprosin and CTRP6 expression in subcutaneous and retroperitoneal adipose tissues in rats during mid-gestation].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Serum concentration of asprosin in new-onset type 2 diabetes.Diabetology & metabolic syndrome · 2020Article
- Asprosin: A Novel Player in Metabolic Diseases.Frontiers in endocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asprosin is a counter-regulatory hormone to insulin which plays a role in fasting. It may therefore also play a role in hypoglycaemia unawareness, which has been subsequently examined in this pilot study. Intravenous glucose tolerance test was used to induce controlled hyperglycemia whereas a hyperinsulinemic clamp test was used to induce a controlled hypoglycaemia in 15 patients with diabetes type 1, with and without hypoglycaemia unawareness. Changes in asprosin plasma levels did not differ between patients with and without hypoglycaemia unawareness. However, nine patients with insulin resistance as well as higher liver stiffness values and low-density lipoprotein but lower high-density lipoprotein levels did not show the expected increase in asprosin plasma levels during hypoglycemia. Therefore, insulin resistance and alterations in liver structure, most likely early stages of non-alcoholic fatty liver disease, seem to be relevant in type 1 diabetes and do not only lead to elevated plasma levels of asprosin, but also to a blunted asprosin response in hypoglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.